Literature DB >> 20123210

Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model.

Julien Namur1, Michel Wassef, Jean-Marc Millot, Andrew L Lewis, Michel Manfait, Alexandre Laurent.   

Abstract

PURPOSE: To evaluate the local tissue concentrations of the antineoplastic agent doxorubicin and the amount of drug still present inside drug delivery embolization beads at different time points after embolization and to compare doxorubicin levels with histologic modifications around the beads in a pig liver model. It was hypothesized that doxorubicin-eluting beads maintain cytotoxic concentrations of drug locally over a period of several weeks, as suggested by in vitro elution tests.
MATERIALS AND METHODS: Left lobe hepatic artery embolization was performed in 10 pigs with 100-300-microm or 700-900-microm beads loaded with 37.5 mg doxorubicin/mL. Control unloaded 100-300-microm beads were injected in five pigs. Livers were sampled 28 days or 90 days after embolization. The amount of drug retained inside the beads was assessed with infrared microspectroscopy. Doxorubicin concentration and distribution in the tissue around the beads were determined with microspectrofluorimetry and compared with tissue modifications on hematein eosin saffron-stained sections.
RESULTS: Doxorubicin-eluting beads eluted 43% of their initial drug load after 28 days and 89% after 90 days. Doxorubicin was present in tissues around the beads at both time points, with a significant decrease over time (P = .0004). The drug was detected at distances as far as 600 microm from the bead edge. Doxorubicin tissue concentrations ranged from 0.55 microM to 6.80 microM, [corrected] which are cytotoxic levels in hepatocyte cell cultures. High concentrations of drug were associated with coagulative necrosis of liver parenchyma. Doxorubicin-eluting beads 100-300 microm in size induced more necrosis than 700-900-microm beads (P = .0036).
CONCLUSIONS: Doxorubicin-eluting beads deliver high concentrations of the drug over a period of at least 3 months at several hundred micrometers from the bead, leading to significant cytotoxic effects. Copyright (c) 2010 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20123210     DOI: 10.1016/j.jvir.2009.10.026

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  29 in total

Review 1.  Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy.

Authors:  Andrew L Lewis; Matthew R Dreher
Journal:  J Control Release       Date:  2012-01-21       Impact factor: 9.776

Review 2.  Advances in Biomaterials and Technologies for Vascular Embolization.

Authors:  Jingjie Hu; Hassan Albadawi; Brian W Chong; Amy R Deipolyi; Rahul A Sheth; Ali Khademhosseini; Rahmi Oklu
Journal:  Adv Mater       Date:  2019-06-06       Impact factor: 30.849

Review 3.  Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?

Authors:  Thierry de Baere; Lambros Tselikas; Frederic Deschamps; Valerie Boige; Michel Ducreux; Antoine Hollebecque
Journal:  Hepat Oncol       Date:  2016-03-23

4.  Characterization of a novel intrinsically radiopaque Drug-eluting Bead for image-guided therapy: DC Bead LUMI™.

Authors:  Koorosh Ashrafi; Yiqing Tang; Hugh Britton; Orianne Domenge; Delphine Blino; Andrew J Bushby; Kseniya Shuturminska; Mark den Hartog; Alessandro Radaelli; Ayele H Negussie; Andrew S Mikhail; David L Woods; Venkatesh Krishnasamy; Elliot B Levy; Bradford J Wood; Sean L Willis; Matthew R Dreher; Andrew L Lewis
Journal:  J Control Release       Date:  2017-02-08       Impact factor: 9.776

Review 5.  Polymeric materials for embolic and chemoembolic applications.

Authors:  Azadeh Poursaid; Mark Martin Jensen; Eugene Huo; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2016-02-26       Impact factor: 9.776

Review 6.  Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice.

Authors:  Nathan X Chai; Julius Chapiro
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

7.  Evaluation of 70-150-μm doxorubicin-eluting beads for transcatheter arterial chemoembolization in the rabbit liver VX2 tumour model.

Authors:  Ali Gholamrezanezhad; Sahar Mirpour; Jean-Francois H Geschwind; Pramod Rao; Romaric Loffroy; Olivier Pellerin; Eleni A Liapi
Journal:  Eur Radiol       Date:  2016-01-15       Impact factor: 5.315

Review 8.  Treatment of intermediate-stage hepatocellular carcinoma.

Authors:  Alejandro Forner; Marine Gilabert; Jordi Bruix; Jean-Luc Raoul
Journal:  Nat Rev Clin Oncol       Date:  2014-08-05       Impact factor: 66.675

9.  Hepatocellular carcinoma cells surviving doxorubicin treatment exhibit increased migratory potential and resistance to doxorubicin re-treatment in vitro.

Authors:  Sebastian Buschauer; Andreas Koch; Philipp Wiggermann; Martina Müller; Claus Hellerbrand
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

10.  Contrast-enhanced ultrasound after devascularisation of neuroendocrine liver metastases: functional and morphological evaluation.

Authors:  Aymeric Guibal; Thibaud Lefort; Laurence Chardon; Noura Benslama; Sébastien Mulé; Franck Pilleul; Catherine Lombard-Bohas; Lori Bridal; Jean Alain Chayvialle; Olivier Lucidarme; Alban Denys; Thomas Walter
Journal:  Eur Radiol       Date:  2012-09-22       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.